Savara Updates Series B Funding Tranche to $14.3 Million
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Savara Inc. has updated a previously reported tranche of Series B round financing to $14.3 million. The Austin-based company, which develops pulmonary drugs, collected the capital from 239 investors, according to a Wednesday filing with the U.S. Securities and Exchange Commission. Savara reported in March raising a $7.4 million second tranche of its funding round. The $14.3 million is in addition to an $8.6 million first tranche completed in June 2012.
Help employers find you! Check out all the jobs and post your resume.
Savara Inc. has updated a previously reported tranche of Series B round financing to $14.3 million. The Austin-based company, which develops pulmonary drugs, collected the capital from 239 investors, according to a Wednesday filing with the U.S. Securities and Exchange Commission. Savara reported in March raising a $7.4 million second tranche of its funding round. The $14.3 million is in addition to an $8.6 million first tranche completed in June 2012.
Help employers find you! Check out all the jobs and post your resume.